Enalapril

Enalapril

SCHEMBL9

CCOC(=O)[C@H](CCc1ccccc1)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)O.O=C(O)/C=C\C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACE

The experimentally established mechanism targets of Enalapril. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
ACE known ✓ P12821 14/20 0.91
SMN1; SMN2 Q16637 1/20 1.00
LMNA P02545 2/20 0.91
ABCB11 O95342 2/20 0.65
MEN1 O00255 2/20 0.63
KMT2A Q03164 2/20 0.63
USP2 O75604 1/20 0.63
CYP3A4 P08684 1/20 0.63
ALOX15 P16050 1/20 0.63
PDE3A Q14432 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Enalapril SCHEMBL20817249 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL10 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL2719411 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL6155137 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL10390115 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL1650291 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL308603 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL825430 1.00 SMN1; SMN2 (1.00) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL9019924 0.99 SMN1; SMN2 (0.98) SMN1; SMN2ACELMNAABCB11MEN1
Enalapril SCHEMBL9019927 0.99 SMN1; SMN2 (0.98) SMN1; SMN2ACELMNAABCB11MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 47814 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4286269-B1 SHIP PROPULSION DEVICE AND BATTERY TEMPERATURE ADJUSTMENT METHOD PANASONIC IP MAN CO LTD (JP) 2026-05-27 EP claimed
EP-4005174-B1 SECURITY LAYER FOR CONFIGURING BLOCKCHAIN IBM (US) 2026-05-27 EP claimed
EP-4365012-B1 CHARGING SYSTEM AND ELECTRIC VEHICLE HUAWEI DIGITAL POWER TECH CO LTD (CN) 2026-05-27 EP claimed
EP-4300992-B1 A HEARING AID COMPRISING A COMBINED FEEDBACK AND ACTIVE NOISE CANCELLATION SYSTEM OTICON AS (DK) 2026-05-27 EP claimed
EP-4411637-B1 TARGET TRACKING METHOD AND APPARATUS HUAWEI TECH CO LTD (CN) 2026-05-27 EP claimed
EP-4534998-B1 GALVANICALLY ISOLATED GAS SENSING SYSTEM FOR AEROSPACE APPLICATIONS KIDDE TECH INC (US) 2026-05-27 EP claimed
EP-4116725-B1 TRANSMISSION DEVICE AND DATA TRANSMISSION METHOD HUAWEI TECH CO LTD (CN) 2026-05-27 EP claimed
EP-3980244-B1 FUNCTIONAL MATERIALS WITH EMBEDDED MEMORY USING SEQUENCE-CONTROLLED POLYMER-BASED STORAGE ETH ZUERICH (CH) 2026-05-27 EP claimed
EP-4381981-B1 MODULAR HELMET SYSTEM BREMICKER SOEHNE KG A (DE) 2026-05-27 EP claimed
EP-4206731-B1 TARGET TRACKING METHOD AND DEVICE YINWANG INTELLIGENT TECH CO LTD (CN) 2026-05-27 EP claimed
EP-0156322-A2 Renin inhibitors containing peptide isosteres MERCK & CO. INC. (US) 1985-10-02 EP claimed
EP-0156318-A2 C-terminal amide cyclic renin inhibitors containing peptide isosteres MERCK & CO. INC. (US) 1985-10-02 EP claimed
EP-0129189-A2 Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same MERCK & CO. INC. (US) 1984-12-27 EP claimed
EP-0129136-A2 Antihypertensive composition MERCK & CO. INC. (US) 1984-12-27 EP claimed
US-4472384-A INTERPHENYLENE 9-THIA-11-OXO-12-AZA PROSTANOIC ACID DERIVATIVE AND CARBOXYALKYLDIPEPTIDE MERCK & CO., INC. (US) 1984-09-18 US claimed
US-4440740-A α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption MERCK & CO., INC. (US) 1984-04-03 US claimed
EP-0083032-A2 Rectally administrable suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1983-07-06 EP claimed
US-4374829-A Aminoacid derivatives as antihypertensives MERCK & CO., INC. (US) 1983-02-22 US claimed
EP-0036145-A1 An orally administered drug form comprising a polar bioactive agent and an adjuvant INTERx RESEARCH CORPORATION (US) 1981-09-23 EP claimed
EP-0031561-A2 A rectally administered suppository comprising a drug and an adjuvant MERCK & CO. INC. (US) 1981-07-08 EP claimed